ストックスクリーナーアプリを入手
13.68
1.23%
-0.17
アフターアワーズ：
13.68
前日終値:
$13.85
開ける：
$13.95
24時間の取引高:
1.36M
Relative Volume:
0.48
時価総額：
$2.07B
収益：
-
当期純損益:
$-647.68M
株価収益率:
-2.4127
EPS:
-5.67
ネットキャッシュフロー:
$-594.49M
1週間 パフォーマンス:
-5.39%
1か月 パフォーマンス:
-4.47%
6か月 パフォーマンス:
+15.35%
1年 パフォーマンス:
-12.36%
1日の値動き範囲:
$13.56
$14.00
1週間の範囲:
$13.26
$14.52
52週間の値動き範囲:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Compare BHVN vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.68 | 2.04B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-06 | 開始されました | Goldman | Buy |
| 2026-01-21 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-06 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 開始されました | Citigroup | Buy |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-09-16 | 開始されました | Jefferies | Buy |
| 2024-09-04 | 開始されました | Bernstein | Outperform |
| 2024-07-24 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2023-12-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-01-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-04 | 開始されました | JP Morgan | Overweight |
| 2022-12-02 | 開始されました | BTIG Research | Buy |
| 2022-10-26 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 開始されました | Piper Sandler | Overweight |
| 2022-08-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-05-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-10 | ダウングレード | UBS | Buy → Neutral |
| 2021-08-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-03-11 | 開始されました | UBS | Buy |
| 2020-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-17 | 開始されました | Cowen | Outperform |
| 2020-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2019-11-22 | 開始されました | Wedbush | Outperform |
| 2019-06-25 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-05-06 | 開始されました | Goldman | Buy |
| 2019-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 繰り返されました | Needham | Buy |
| 2018-07-03 | 繰り返されました | Needham | Buy |
| 2018-07-02 | 繰り返されました | Needham | Buy |
| 2018-04-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-03 | 繰り返されました | Needham | Buy |
すべてを表示
Biohaven Ltd (BHVN) 最新ニュース
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - simplywall.st
HC Wainwright Decreases Earnings Estimates for Biohaven - MarketBeat
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biohaven (BHVN) Pulls Back 1.4% as Shares Approach Key $13.91 Support ZoneChannel Breakout - vinanet.vn
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP - MarketBeat
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? - Sahm
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Yahoo Finance
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven - Stock Titan
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven 2Q Loss/Shr 91c >BHVN - Moomoo
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven Pharma stock price target raised to $23 by RBC Capital - Investing.com Nigeria
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews
Biohaven (BHVN) Holds Near Key Support After Modest PullbackPre-Earnings Momentum - vinanet.vn
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Biohaven narrows Q2 losses 29%, initiates pivotal Graves' trial - scanx.trade
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending - Kalkine Media
Biohaven reports Q2 2026 net loss of $137.3M, cash and marketable securities $267.9M - TradingView
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity - Stock Titan
Biohaven Ltd. reports results for the quarter ended June 30Earnings Summary - TradingView
Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Biohaven earnings set to show cash burn ahead of epilepsy data - Investing.com UK
Understanding Momentum Shifts in (BHVN) - Stock Traders Daily
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven (BHVN) Institutional Ownership 2026 - MarketBeat
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide? - simplywall.st
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Morningstar
Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances - citybiz
Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026 - marketscreener.com
Press Release: Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 71.53% Potential Upside in the Biotech Sector - directorstalkinterviews.com
Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday - MarketBeat
Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC - MarketBeat
Stempoint Capital LP Takes $13.49 Million Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy - simplywall.st
Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications
Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360
Why is Biohaven Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News
Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal
Biohaven and Yale win $4M verdict in trade secret case - Investing.com Nigeria
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - TradingView
Biohaven Ltd (BHVN) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):